Evaxion Biotech Statistics

Total Valuation

Evaxion Biotech has a market cap or net worth of $10.42 million. The enterprise value is $14.57 million.

Market Cap	10.42M
Enterprise Value	14.57M

Important Dates

The next estimated earnings date is Tuesday, May 27, 2025, before market open.

Earnings Date	May 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Evaxion Biotech has 6.32 million shares outstanding. The number of shares has increased by 96.24% in one year.

Current Share Class	n/a
Shares Outstanding	6.32M
Shares Change (YoY)	+96.24%
Shares Change (QoQ)	-2.92%
Owned by Insiders (%)	5.42%
Owned by Institutions (%)	4.11%
Float	4.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.53
Forward PS	1.02
PB Ratio	-6.31
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.01

Current Ratio	2.01
Quick Ratio	1.79
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-15.31

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-72.57%
Return on Invested Capital (ROIC)	-126.22%
Return on Capital Employed (ROCE)	-181.50%
Revenue Per Employee	$72,696
Profits Per Employee	-$229,717
Employee Count	46
Asset Turnover	0.26
Inventory Turnover	n/a

Taxes

Income Tax	-788,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -92.06% in the last 52 weeks. The beta is -0.25, so Evaxion Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.25
52-Week Price Change	-92.06%
50-Day Moving Average	1.83
200-Day Moving Average	8.46
Relative Strength Index (RSI)	52.34
Average Volume (20 Days)	78,633

Short Selling Information

Short Interest	23,309
Short Previous Month	41,825
Short % of Shares Out	0.49%
Short % of Float	n/a
Short Ratio (days to cover)	0.33

Income Statement

In the last 12 months, Evaxion Biotech had revenue of $3.34 million and -$10.57 million in losses. Loss per share was -$9.85.

Revenue	3.34M
Gross Profit	3.34M
Operating Income	-14.73M
Pretax Income	-22.92M
Net Income	-10.57M
EBITDA	-14.37M
EBIT	-14.73M
Loss Per Share	-$9.85

Full Income Statement

Balance Sheet

The company has $5.95 million in cash and $10.10 million in debt, giving a net cash position of -$4.15 million or -$0.66 per share.

Cash & Cash Equivalents	5.95M
Total Debt	10.10M
Net Cash	-4.15M
Net Cash Per Share	-$0.66
Equity (Book Value)	-1.65M
Book Value Per Share	-1.18
Working Capital	4.40M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-12.94M
Capital Expenditures	n/a
Free Cash Flow	-12.94M
FCF Per Share	-$2.05

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-440.55%
Pretax Margin	-339.56%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Evaxion Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-96.24%
Shareholder Yield	n/a
Earnings Yield	-101.39%
FCF Yield	-124.16%

Analyst Forecast

The average price target for Evaxion Biotech is $10.00, which is 509.76% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	509.76%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	85.83%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 14, 2025. It was a reverse split with a ratio of 0.2:1.

Last Split Date	Jan 14, 2025
Split Type	Reverse
Split Ratio	0.2:1

Scores

Evaxion Biotech has an Altman Z-Score of -15.71 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-15.71
Piotroski F-Score	3